High expression of ISG20 predicts a poor prognosis in acute myeloid leukemia

Xiong, Hao; Zhang, Xinwen; Chen, Xiaomin; Liu, Yang; Duan, Jialin; Huang, Chunlan

doi:10.3233/cbm-210061

Cited by 4 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ISG20 level has been reported to be overexpressed in 65.9% (145 out of 220) cancerous tissues compared to concordant adjacent tissues in analyzes with databases [37]. While supporting the progression of the disease [16,38,39], high expression in AML is an indicator of poor prognosis [40]. We found that the expression of ISG20 mRNA was signi cantly increased in MM than the control group.…”

Section: Discussionmentioning

confidence: 60%

TMED9 is a Predictive Marker of Transition from Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma

Sarıman

Yaylaz

Ayer

et al. 2022

Preprint

View full text Add to dashboard Cite

Purpose: Plasma Cell Dyscrasias are a heterogeneous group of hematological diseases. The candidate ten genes identified from our transcriptome data are highly valuable and specific. Methods: We investigated the prognostic biomarker status of these genes in Plasma Cell Dyscrasias. Expression levels of ISG20, EEF2, TRIB1, RRBP1, TMED9, KDELR1, DNAJC1, DPP7, COPE and LMAN2 genes were measured via qRT-PCR from bone marrow samples of 38 Multiple Myeloma, 23 MGUS and 16 control groups. Results: According to our results, in the Multiple Myeloma group, all genes were more highly expressed than control and MGUS groups (p<0.05) In addition, the striking correlation with anemia factors, calcium and Durie Salmon Staging indicates that DNAJC1 is an important risk factor for MM (p<0.05). TMED9 was another prominent gene that showed higher expression in Multiple Myeloma compared to other groups. Also, there was strong association between TMED9 gene expression and clinical parameters of urea, Ca, albumin, LDH, and IGA levels (p<0.05) Moreover, TMED9gene in our results sheds light on myeloma genesis. Conclusion: This study contributed significantly to the search on prognostic biomarkers for Multiple Myeloma progression from MGUS and for starting early treatment in MGUS.

show abstract

Section: Discussionmentioning

confidence: 60%

TMED9 is a Predictive Marker of Transition from Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma

Sarıman

Yaylaz

Ayer

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…ISG20 can cleave single-stranded RNA or DNA and is significantly associated with host antiviral innate immune defense [ 12 , 13 ]. Several reports also suggest a link between ISG20 and the tumorigenic process of multiple neoplasms, including glioma [ 14 ], oral tumor [ 15 ], clear cell renal cell carcinoma [ 16 ], hepatocellular carcinoma [ 17 ], breast cancer [ 18 ], and acute myeloid leukemia [ 19 ], although the exact ISG20 pathomechanism remains unclear.…”

Section: Introductionmentioning

confidence: 99%

Integrated bioinformatics analysis and experimental validation reveal ISG20 as a novel prognostic indicator expressed on M2 macrophage in glioma

Peng

Liu

et al. 2023

BMC Cancer

View full text Add to dashboard Cite

Background Glioma is the most common malignant primary brain tumor and is characterized by a poor prognosis and limited therapeutic options. ISG20 expression is induced by interferons or double-stranded RNA and is associated with poor prognosis in several malignant tumors. Nevertheless, the expression of ISG20 in gliomas, its impact on patient prognosis, and its role in the tumor immune microenvironment have not been fully elucidated. Methods Using bioinformatics, we comprehensively illustrated the potential function of ISG20, its predictive value in stratifying clinical prognosis, and its association with immunological characteristics in gliomas. We also confirmed the expression pattern of ISG20 in glioma patient samples by immunohistochemistry and immunofluorescence staining. Results ISG20 mRNA expression was higher in glioma tissues than in normal tissues. Data-driven results showed that a high level of ISG20 expression predicted an unfavorable clinical outcome in glioma patients, and revealed that ISG20 was possibly expressed on tumor-associated macrophages and was significantly associated with immune regulatory processes, as evidenced by its positive correlation with the infiltration of regulatory immune cells (e.g., M2 macrophages and regulatory T cells), expression of immune checkpoint molecules, and effectiveness of immune checkpoint blockade therapy. Furthermore, immunohistochemistry staining confirmed the enhanced expression of ISG20 in glioma tissues with a higher WHO grade, and immunofluorescence assay verified its cellular localization on M2 macrophages. Conclusions ISG20 is expressed on M2 macrophages, and can serve as a novel indicator for predicting the malignant phenotype and clinical prognosis in glioma patients.

show abstract

FOSL2-mediated transcription of ISG20 induces M2 polarization of macrophages and enhances tumorigenic ability of glioblastoma cells

Du,

Sun,

Wang

et al. 2024

J Neurooncol

View full text Add to dashboard Cite

High expression of ISG20 predicts a poor prognosis in acute myeloid leukemia

Cited by 4 publications

References 31 publications

TMED9 is a Predictive Marker of Transition from Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma

TMED9 is a Predictive Marker of Transition from Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma

Integrated bioinformatics analysis and experimental validation reveal ISG20 as a novel prognostic indicator expressed on M2 macrophage in glioma

FOSL2-mediated transcription of ISG20 induces M2 polarization of macrophages and enhances tumorigenic ability of glioblastoma cells

Contact Info

Product

Resources

About